MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.
Animals
Carcinoma, Pancreatic Ductal
/ enzymology
Disease Progression
Epithelial Cells
/ pathology
Female
Gene Knockdown Techniques
Humans
Intracellular Signaling Peptides and Proteins
Macrophages
/ pathology
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Pancreatic Neoplasms
/ enzymology
Proof of Concept Study
Protein Serine-Threonine Kinases
/ genetics
Receptor Protein-Tyrosine Kinases
/ genetics
Signal Transduction
Tumor Microenvironment
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
27
11
2018
accepted:
20
03
2019
revised:
20
03
2019
pubmed:
11
4
2019
medline:
15
2
2020
entrez:
11
4
2019
Statut:
ppublish
Résumé
The MST1R (RON) kinase is overexpressed in >80% of human pancreatic cancers, but its role in pancreatic carcinogenesis is unknown. In this study, we examined the relevance of Mst1r kinase to Kras driven pancreatic carcinogenesis using genetically engineered mouse models. In the setting of mutant Kras, Mst1r overexpression increased acinar-ductal metaplasia (ADM), accelerated the progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the accumulation of (mannose receptor C type 1) MRC1+, (arginase 1) Arg+ macrophages in the tumor microenvironment. Conversely, absence of a functional Mst1r kinase slowed PanIN initiation, resulted in smaller tumors, prolonged survival and a reduced tumor-associated macrophage content. Mst1r expression was associated with increased production of its ligand Mst1, and in orthotopic models, suppression of Mst1 expression resulted in reduced tumor size, changes in macrophage polarization and enhanced T cell infiltration. This study demonstrates the functional significance of Mst1r during pancreatic cancer initiation and progression. Further, it provides proof of concept that targeting Mst1r can modulate pancreatic cancer growth and the microenvironment. This study provides further rationale for targeting Mst1r as a therapeutic strategy.
Identifiants
pubmed: 30967626
doi: 10.1038/s41388-019-0811-9
pii: 10.1038/s41388-019-0811-9
pmc: PMC6625868
mid: NIHMS1525172
doi:
Substances chimiques
Intracellular Signaling Peptides and Proteins
0
STK4 protein, human
EC 2.7.1.11
RON protein
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5599-5611Subventions
Organisme : NCI NIH HHS
ID : R01 CA155620
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA121938
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE027325
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA167426
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226909
Pays : United States
Références
Cancer Cell. 2009 Jun 2;15(6):489-500
pubmed: 19477428
Cancer Res. 2006 Dec 15;66(24):11967-74
pubmed: 17178895
J Immunol. 1999 Dec 15;163(12):6606-13
pubmed: 10586055
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
J Leukoc Biol. 2004 May;75(5):731-7
pubmed: 14726496
Oncotarget. 2015 Jul 10;6(19):17445-61
pubmed: 25938541
Cancer Res. 2010 Feb 1;70(3):1130-40
pubmed: 20103639
Cancer Res. 2007 Jul 1;67(13):6075-82
pubmed: 17616662
Clin Cancer Res. 2010 Jul 15;16(14):3684-95
pubmed: 20534740
Cancer Cell. 2003 Dec;4(6):437-50
pubmed: 14706336
J Leukoc Biol. 2003 Feb;73(2):209-12
pubmed: 12554797
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
Oncoimmunology. 2013 Sep 1;2(9):e25670
pubmed: 24327933
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
J Immunol Methods. 2000 Sep 21;243(1-2):77-97
pubmed: 10986408
J Immunol. 2011 Sep 1;187(5):2181-92
pubmed: 21810604
Oncotarget. 2014 Jul 30;5(14):5547-58
pubmed: 24980820
J Clin Invest. 2001 Aug;108(4):567-76
pubmed: 11518730
Cancer Res. 2003 Nov 1;63(21):7451-61
pubmed: 14612545
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Immunity. 2017 Aug 15;47(2):323-338.e6
pubmed: 28813661
J Clin Oncol. 2015 Jun 1;33(16):1779-86
pubmed: 25918299
PLoS One. 2010 Oct 22;5(10):e13578
pubmed: 21042537
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Cancer Res. 2013 Mar 15;73(6):1752-63
pubmed: 23328584
J Oncol. 2010;2010:201026
pubmed: 20490273
BMC Cancer. 2012 Sep 07;12:395
pubmed: 22958871
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Toxicol Appl Pharmacol. 2012 Jul 15;262(2):139-48
pubmed: 22575169
Oncogene. 2010 Jan 14;29(2):214-26
pubmed: 19838218
Genes Dev. 2003 Dec 15;17(24):3112-26
pubmed: 14681207